v3.25.1
Segments (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Reportable Segment Loss

The following table presents reportable segment loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

Chronic cough in IPF clinical trial expense

 

$

14,615

 

 

$

5,867

 

Refractory chronic cough clinical trial expense

 

 

6,042

 

 

 

2,383

 

Other clinical trials and studies 1

 

 

4,313

 

 

 

4,410

 

Clinical trial material

 

 

3,235

 

 

 

2,216

 

Other clinical development expenses 2

 

 

4,008

 

 

 

3,154

 

Employee compensation (excluding stock compensation expense)

 

 

9,265

 

 

 

7,883

 

Stock compensation expense

 

 

3,588

 

 

 

2,247

 

Other segment items 3

 

 

6,447

 

 

 

5,653

 

Interest income, net

 

 

(3,602

)

 

 

(4,748

)

Net loss

 

$

47,911

 

 

$

29,065

 

 

(1) Includes expense related to the Company’s Human Abuse Potential study, the Company’s Phase 2a CANAL trial of Haduvio for the treatment of chronic cough in patients with IPF, and the Company’s Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis.

(2) Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.

(3) Includes general administrative expense, interest expense, net, other (expense) income, net and income tax benefit.